Catalent achieves global ISO accreditation
Company is one of the first CDMOs to receive award.
Catalent has announced that the British Standards Institute (BSI) has awarded Catalent a global accreditation against the international management standards for environment (ISO14001:2015) and occupational safety (OHSAS18001:2007). The accreditation, for Catalent’s global Environment, Health & Safety (EHS) management system is one of the first to be awarded in the pharmaceutical industry to a CDMO.
BSI’s auditors judged that Catalent’s EHS system demonstrates a high degree of sophistication and maturity, and competes at a world-class performance level with other leading industries and businesses.
“Our EHS system drives our core values of injury prevention and environmental sustainability, and is central to supporting customer and patient expectations,” commented Mark Incledion, Catalent’s Global Director, EHS. He added: “This accreditation is very much in line with Catalent's patient-first and corporate responsibility-driven philosophy, while helping us meet our environmental targets and promote a cleaner planet.”
Catalent’s global network of facilities produce over 70 billion doses annually and are approved by 35 regulatory agencies to provide flexible commercial and clinical manufacturing supplies in oral, sterile, biologic and inhaled dose forms for customers around the world.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.